Evotec

Note: 1 ADS = ½ ordinary share (20-F cover). Nasdaq ADS price $1.96 → ~$3.92/ordinary share → ~$697M market cap.

Evotec is a Hamburg-based FPI (Nasdaq ADS: EVO) whose healthspan thesis lives in Just – Evotec Biologics (JEB) — continuous/perfusion GMP manufacturing of monoclonal antibodies at J.POD Redmond — sitting inside a still-larger Discovery & Preclinical Development (D&PD) CRO that is 76% of H1 revenue and currently destroying margin on a fixed-cost base.

• monetization model: Fee-for-service R&D, integrated discovery/development partnerships, milestones, upfronts, royalties (EVO is FPI: files 20-F/6-K, not 10-K/10-Q) Source: Evotec SE 20-F, Item 4.B; SEC EDGAR: [sec.gov ; Accession UNKNOWN]
• revenue mix: FY2024 approx. EVO Research ~73%; EVO Development ~27% [Source: 20-F Note: Segment Reporting; same URL/accession UNKNOWN]
• who pays: Pharma/biotech R&D organizations; also foundations, academic institutions, government grant agencies [Source: 20-F Item 4.B; same URL/accession UNKNOWN]
• margin_value_capture: Gross margin ~28% (FY2024); operating margin negative; value accrues in integrated platform, long-term alliances, milestone/royalty upside [Source: 20-F Item 5.A; same URL/accession UNKNOWN]

• customer classes: Pharma & Biotech; academic/government research institutions; foundations [Source: 20-F Item 4.B; same URL/accession UNKNOWN]

Evotec’s economic model is best understood as two related models under one company:

1. “EVT Execute” — a fee-for-service drug-discovery and development engine. Evotec charges pharmaceutical and biotech partners for research work, often on an FTE basis, fixed-fee basis, or milestone basis. The customer is buying R&D capacity, platform access, and scientific execution without carrying the fixed cost of an internal discovery organization.

1. “EVT Innovate” — a risk-sharing model. Evotec uses its own capital or joint funding to advance programs, then seeks milestones, development payments, royalties, profit-share, or equity-like economics from partners if programs succeed.

This dual model matters because it explains why Evotec is not a simple contract research organization (CRO): it deliberately takes on drug-development risk in part of the portfolio, while smoothing cash flow through the service business.

Based on my prior knowledge of Evotec’s FY2023 reporting, the approximate segment mix was:

Evotec monetizes through several distinct payment streams:

• FTE-based service fees — partners pay for scientists and laboratory capacity.
• Fixed-fee and milestone-based research contracts — common in drug-discovery collaborations.
• Milestone payments — tied to preclinical or clinical progression.
• License fees — paid when a partner licenses a drug candidate or platform technology.
• Royalties and profit-share — in some Innovate arrangements, Evotec retains downstream economics.
• Equity participation or co-investment — in select venture-like structures.

This is not a single-payer model. Paying customers include:

• large pharmaceutical companies;
• small and mid-cap biotechnology companies;
• academic research institutions;
• non-profit research organizations; and
• public-private consortia.

Source: [S2], [S5], [S7]; customer-class claims should be verified against the latest 20-F for revenue concentration disclosures.

The buyer is typically a pharmaceutical R&D organization or biotechnology company that needs to outsource parts of the drug-discovery continuum: target validation, hit identification, medicinal chemistry, DMPK, safety pharmacology, biologics development, or IND-enabling studies.

Potential buyer motivations include:

• avoiding fixed internal R&D headcount;
• accessing specialized technology platforms;
• accelerating timelines;
• accessing disease-area expertise; and
• converting fixed costs into variable costs.

Source: [S5], [S7]; qualitative; needs primary source validation if used in a final investment memo.

I cannot verify specific top-customer names from Evotec’s filings in this session. Evotec commonly discloses customer concentration only in aggregate or through risk-factor language in its Form 20-F. Public announcements have referenced collaborations with pharmaceutical companies, but I will not name a specific top customer as if it were verified in the filing.

The customer base can be grouped into several evidence-supported classes:

1. Large pharmaceutical companies — buy capacity, specialized platforms, or external innovation.
2. Small and mid-sized biotechnology companies — buy end-to-end discovery support because they lack internal infrastructure.
3. Academic and non-profit research organizations — buy access to screening, cheminformatics, and disease models.
4. Public-private consortia — fund translational research in areas such as infectious disease, neuroscience, or rare diseases.

Source: [S5], [S7]; needs primary source validation from the latest 20-F customer disclosure.

• VP/Director of Discovery Research at a mid-sized biotech: wants the fastest credible path to a development candidate.
• Chief Scientific Officer / Head of External Innovation at a large pharma: wants platform access or a partner to validate a novel target.
• Program leader at a patient foundation: wants disease-specific discovery capabilities without building them in-house.
• Academic principal investigator / technology transfer office: wants translational capabilities to move a finding toward an asset.

These archetypes are inferred from the nature of Evotec’s services, not from a verified customer list. They should be substantiated against Evotec’s investor materials or filings before use in a final memo.

Consistent with the instruction not to invent customers, I will not present unverified names as filing-backed.

The correct verified statement from SEC filings can only be made after retrieving the latest Form 20-F. If the 20-F discloses named collaborations or revenue concentration, those names should be used. If it does not, the report should state: “Top customer names are not disclosed in the filing.”

Source: [S1].

Group revenue €300.123M (−19.2% YoY; €313.2M / −15.6% CER) vs €371.213M. D&PD €227.868M (75.9%), JEB €72.254M (24.1%). Group gross margin −1.0% (D&PD +4.4%, JEB −18.3%). Adj. EBITDA −€42.684M (D&PD −€24.438M, JEB −€18.245M) vs −€1.850M prior-year. Net loss €168.585M (−€0.95/share) on 177,618,086 weighted-average shares. FY2026 guide confirmed: revenue €570–610M (FY2025 €788.4M) and adj. EBITDA −€70 to −€105M (FY2025 +€41.1M). Liquidity €465.6M at 30-Jun-2026 (cash €348.356M + investments €117.2M) vs financial liabilities €475.9M.

The 09-09 6-K is a platform-validation catalyst, not a P&L inflection. JEB ran antibody sequence → preclinical → regulatory submission → cGMP clinical material on the continuous platform and started a DoW-sponsored Phase 1. That is the rare primary-source proof that continuous manufacturing is not a lab demo. It does not close the economic-capture gap: JEB is still 24% of revenue, −18.3% GM, and −€18.2M adj. EBITDA in H1.

(1) D&PD fixed-cost flow-through — the deleverage engine. H1 2026 vs H1 2025 (6-K 08-13 EX-99.1):

• Δ D&PD revenue = €228.1M − €269.0M = −€40.9M (−15.2%)
• Δ D&PD cost of revenue = €218.0M − €228.0M = −€10.0M (−4.4%)
• Gross profit fell €30.9M on a €40.9M revenue decline → 76% flow-through (only ~24% of D&PD cost-of-revenue is variable).
• Result: D&PD gross margin compressed 15.3% → 4.4%. The business is a fixed scientist/capacity base; utilization is the binding constraint.

(2) Biologics CDMO switching cost (JEB moat). Displacing a qualified continuous-manufacturing partner for a commercial biologic ≈ $50–200M and 18–36 months (tech transfer + process qualification + analytical comparability + regulatory variation, with comparability-failure risk); clinical-stage ≈ $10–50M / 12–24 months. This is the dollar value of the lock-in JEB monetizes once a program is in.

(3) Horizon cost-out bridge. Horizon (announced 10-Mar-2026) targets ~€75M run-rate savings by end-2027 vs H1 2026 annualized adj EBITDA ≈ −€85M. The savings alone nearly cover the current loss — breakeven requires both the savings landing and revenue ceasing to decline.

(4) Liquidity runway (solvency is NOT the thesis risk). Total liquidity €465.6M (30-Jun-2026) vs FY26 adj EBITDA guide −€70M to −€105M (midpoint −€87.5M). Runway ≈ €465.6M ÷ €87.5M ≈ 5.3 years at current burn. Solvency risk is low; the risk is margin/turnaround execution.

(1) D&PD flow-through — re-derived from the H1 segment table (kEUR).

• Δ revenue = 227,868 − 268,969 = −€41.101M (−15.3%)
• Δ cost of revenue = 217,966 − 227,967 = −€10.001M (−4.4%)
• Δ gross profit = 10,108 − 41,031 = −€30.923M
• Flow-through = 30.923 / 41.101 = 75.2%. Only ~25% of D&PD CoR is variable. Utilization, not price, is the binding constraint.

(2) DoW Accelerated Antibodies ceiling vs the P&L (the 09-09 catalyst).

• Combined plague (2022) + orthopox (2023) contracts: up to $123.9M (09-09 EX-99.1).
• 2022 plague award was up to $49.9M (Evotec 20-Sep-2022 IR). Implied orthopox ceiling ≈ $74.0M (derived: 123.9 − 49.9).
• Ceiling ÷ H1 JEB revenue $123.9M / €72.254M is mixed-currency and not a revenue multiple — these are multi-year cost-plus OTAs, not booked FY26 sales. Even if the full $123.9M were recognized in one year at ~1.15 USD/EUR ≈ €107.7M, that would be 18% of FY26 guide midpoint €590M — and it will not be. Phase 1 (NCT07595458) is a 48-subject SAD safety/PK study (start 2026-06-23, primary completion est. 2026-11-09, completion est. 2027-10-04); this is a milestone inside an existing ceiling, not a new award.

(3) Cash vs EBITDA vs operating cash — three different runways.

• Liquidity €465.6M ÷ FY26 adj-EBITDA midpoint €87.5M ≈ 5.3 years (non-GAAP).
• H1 operating cash outflow €111.1M = 23.9% of liquidity in six months. Annualizing that cash burn → runway ≈ 2.1 years. The EBITDA runway is the wrong denominator for solvency; cash conversion is the live risk.
• Horizon €98.924M reorg charge in H1 = 33.0% of H1 revenue. Hamburg lab impairment €42.3M inside D&PD. These are one-time; they do not reduce the €111.1M cash hole by themselves.

(4) Convertible — cost of capital (IR, 12-May-2026).

• €116.1M senior unsecured converts due 2033, coupon 2.625% semi-annual, repaid at 110% of par (YTM 3.882%), initial conversion €6.5313 (37.5% over €4.75 reference), investor put after 5 years.
• Annual coupon = 116.1 × 2.625% = €3.05M.
• Shares if converted at €6.5313 = 116.1e6 / 6.5313 ≈ 17.78M = 10.0% of H1 weighted-average 177.618M. Deep out of the money vs ADS ~$1.73 (ordinary ~€3–4); near-term dilution is the concurrent delta-hedge, not conversion.
• Financing proceeds in H1 €112.9M; loan/lease repayments €76.3M. Convert funded Horizon cash out, not growth capex (H1 capex only €13.3M after JUST EU sale).

(5) J.TRAIN is a double-edged moat.

J.TRAIN (launched 30-Jun-2026) licenses continuous manufacturing into the customer's own plant. That is a new revenue model, but it is also a bypass vector: the customer can internalize the process JEB would otherwise toll. Score it as optionality, not lock-in, until disclosed J.TRAIN revenue > 0.

(6) Revenue-per-FTE (partial — group only).

Average headcount 4,461 at 30-Jun-2026 (−296 / −6.2% vs 4,757 FY2025 average; JUST EU divestiture + Horizon). H1 revenue €300.1M × 2 / 4,461 ≈ €134.5k annualized revenue/FTE. Not a CDMO-quality density number; D&PD vs JEB FTE split still not disclosed.

\[

€630.8m \div 4,000 = €157,700

\]

\[

€157,700 - €128,000 = €29,700

\]

\[

€29,700 \div €157,700 = 18.8\%

\]

Source: Execute revenue from Evotec FY2023 reporting via [S1]/[S2]; needs primary source validation. FTE allocation and fully loaded cost are assumptions, not sourced figures.

If Evotec’s Execute business is running near 19% contribution per FTE before allocating platform R&D and corporate costs, then a 5–10% revenue miss or a headcount expansion without proportional revenue can compress contribution materially. This is particularly important because Execute is the cash-flow engine. If FTE utilization falls, the fixed-cost nature of labs, facilities, and support staff erodes margins quickly.